BioTrove, Gene Express to Co-Market Lung Cancer Risk Test | GenomeWeb
NEW YORK (GenomeWeb News) – BioTrove and Gene Express have struck an agreement to co-market a test for profiling certain indicators for the risk of lung cancer, BioTrove said today.
 
The test, called the Standardized NanoArray PCR, or SNAP, gene expression profiling system, uses BioTrove’s OpenArray nanofluidic PCR platform, Gene Express’ PCR measurement standards, and clinical knowledge from the University of Rochester School of Medicine and Dentistry.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.